Literature DB >> 3806219

Diagnostic significance of indium-111 granulocyte scintigraphy in febrile patients.

M T Syrjälä, V Valtonen, K Liewendahl, G Myllylä.   

Abstract

Sixty-eight patients with fever of unknown origin, 32 patients with postoperative fever, and 26 patients with therapy-resistant fever after bacteremia were investigated with [111In] granulocyte scintigraphy for the detection of abscesses. The results showed that the value of [111In]granulocyte scintigraphy in the detection of infectious foci vary in these three types of febrile conditions. The overall sensitivity and specificity were 86.5% and 87.8%, respectively. We observed, however, a relatively low predictive value of a positive result in the fever of unknown origin group (73.1%), and also a low predictive value of a negative result in the bacteremia group (66.7%). The C-reactive protein (CRP) levels in patients with a true-positive scintigram were significantly (p less than 0.001) higher than in patients with a true-negative scintigram. There was also a significant positive correlation (p less than 0.01) between the serum CRP concentration and the intensity of the granulocyte accumulations. There was no correlation between the peripheral leukocyte count or the erythrocyte sedimentation rate (ESR) and the intensity of the granulocyte uptake. Therefore CRP, but not the leukocyte count or ESR, appears useful for selecting the patients who benefit most from granulocyte scintigraphy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3806219

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

Review 1.  The use of nuclear medicine techniques in the emergency department.

Authors:  B S McGlone; K K Balan
Journal:  Emerg Med J       Date:  2001-11       Impact factor: 2.740

2.  Role of integrated PET/CT with [¹⁸F]-FDG in the management of patients with fever of unknown origin: a single-centre experience.

Authors:  E Pelosi; A Skanjeti; D Penna; V Arena
Journal:  Radiol Med       Date:  2011-03-07       Impact factor: 3.469

3.  Disappearing hot spot on an indium 111 white cell scan: a case report.

Authors:  Sanjiv Petkar; Tahir Hamid; Brian Pendegrast; Clifford Garratt; Parthiban Arumugam
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

4.  Intestinal accumulation of 111In-granulocytes in patients studied because of occult infection.

Authors:  M T Syrjälä; K Liewendahl; V Valtonen; J Gripenberg
Journal:  Eur J Nucl Med       Date:  1987

5.  Accumulation of leucocytes labelled with technetium-99m hexamethylpropylene amine oxime in malignant abdominal tumours.

Authors:  E Lantto; K Järvi; T Lantto; S Ristkari; M Vorne
Journal:  Eur J Nucl Med       Date:  1991

6.  Intense accumulation of indium-111 leukocytes in peritonitis carcinomatosa.

Authors:  N Ishikawa; T Takeda; K Nakajima; M Satoh; A A Qureshi; M Akisada; T Todoroki; K Orii; K Saitoh
Journal:  Ann Nucl Med       Date:  1989-03       Impact factor: 2.668

7.  Localising the cause of an undiagnosed fever.

Authors:  A M Peters
Journal:  Eur J Nucl Med       Date:  1996-03

Review 8.  Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Rakesh Kumar; Sandip Basu; Drew Torigian; Vivek Anand; Hongming Zhuang; Abass Alavi
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

9.  Fever of unknown origin: prospective comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy.

Authors:  Andreas Kjaer; Anne-Mette Lebech; Annika Eigtved; Liselotte Højgaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-17       Impact factor: 9.236

10.  Diagnostic value of [(18)F]-FDG PET/CT in children with fever of unknown origin or unexplained signs of inflammation.

Authors:  Niklas Jasper; Jan Däbritz; Michael Frosch; Markus Loeffler; Matthias Weckesser; Dirk Foell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.